Meeting
2023 ASCO Genitourinary Cancers Symposium
89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX.
Authors
Andrei Iagaru
Division of Nuclear Medicine and Molecular Imaging,Stanford University, Stanford, CA
Andrei Iagaru , Amol Madan Takalkar , Geoffrey Stuart Higgins , Jackson William Kiser , Libuse Tauchmanova , Sapna Shah , Kavita Vadali , Colin Hayward , James Robert Crowley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT05563272
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS738)
DOI
10.1200/JCO.2023.41.6_suppl.TPS738
Abstract #
TPS738
Poster Bd #
M16
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Results of a feasibility study of I-124 girentuximab in metastatic clear cell renal cell carcinoma (m ccRCC).
First Author: Stephen Michael Keefe
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
First Author: Carlos Rojas
Poster
2023 ASCO Annual Meeting
Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.
First Author: Elshad Hasanov
Poster
2023 ASCO Genitourinary Cancers Symposium
STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC).
First Author: Darren R. Feldman